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OBJECTIVE—Recent genome-wide association studies have
resulted in a dramatic increase in our knowledge of the genetic
loci involved in type 2 diabetes. In a complementary approach to
these single-marker studies, we attempted to identify biological
pathways associated with type 2 diabetes. This approach could
allow us to identify additional risk loci.
RESEARCH DESIGN AND METHODS—We used individual
level genotype data generated from the Wellcome Trust Case
Control Consortium (WTCCC) type 2 diabetes study, consisting
of 393,143 autosomal SNPs, genotyped across 1,924 case subjects
and 2,938 control subjects. We sought additional evidence from
summary level data available from the Diabetes Genetics Initia-
tive (DGI) and the Finland-United States Investigation of NIDDM
Genetics (FUSION) studies. Statistical analysis of pathways was
performed using a modiﬁcation of the Gene Set Enrichment
Algorithm (GSEA). A total of 439 pathways were analyzed from
the Kyoto Encyclopedia of Genes and Genomes, Gene Ontology,
and BioCarta databases.
RESULTS—After correcting for the number of pathways tested,
we found no strong evidence for any pathway showing associa-
tion with type 2 diabetes (top Padj  0.31). The candidate
WNT-signaling pathway ranked top (nominal P  0.0007, exclud-
ing TCF7L2; P  0.002), containing a number of promising single
gene associations. These include CCND2 (rs11833537; P 
0.003), SMAD3 (rs7178347; P  0.0006), and PRICKLE1
(rs1796390; P  0.001), all expressed in the pancreas.
CONCLUSIONS—Common variants involved in type 2 diabetes
risk are likely to occur in or near genes in multiple pathways.
Pathway-based approaches to genome-wide association data
may be more successful for some complex traits than others,
depending on the nature of the underlying disease physiology.
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R
ecent genome-wide association (GWA) studies
have resulted in a dramatic increase in our
knowledge of the genetic loci involved in type 2
diabetes. There are now 18 common variants
with robust evidence of association with the disease (1–7).
Individually, these variants only have a small effect on
disease risk, and in combination they account for only
3% of the heritability of type 2 diabetes (6). GWA studies
have focused on only the most statistically strongly asso-
ciated individual variants, with robust association being
declared only if a variant meets a stringent “genome-wide”
level of statistical signiﬁcance. However, GWA studies of a
few thousand individuals are underpowered to detect
variants with odds ratios of 1.2 at P  1  10
5—the
typical P values used to take SNPs forward into replication
studies. This means many real type 2 diabetes predispos-
ing variants may not be detected in GWA data and are not
yet followed up. The most robust way of testing for these
variants is to increase sample sizes, and such efforts are
ongoing. However, ever larger numbers of case and con-
trol subjects may be difﬁcult to obtain. We therefore
sought alternative approaches to investigating GWA data.
RESEARCH DESIGN AND METHODS
Samples. For the initial analysis, we used individual-level genotype data
generated from the Wellcome Trust Case Control Consortium (WTCCC) type
2 diabetes study. Quality-control criteria and study design are described in
detail in Zeggini et al. (7). We used a total of 393,143 autosomal single
nucleotide polymorphisms (SNPs), in 1,924 case subjects and 2,938 popula-
tion-based control subjects.
We used summary association statistics from two type 2 diabetes GWA
studies for validation. These are the Diabetes Genetics Initiative (DGI) and the
Finland-United States Investigation of NIDDM Genetics (FUSION) study,
which together consist of 2,625 case subjects and 2,641 control subjects
(2,3,6). Imputed SNP association statistics were used for any FUSION or DGI
SNPs that were missing or not directly genotyped. Only those with high
imputation conﬁdence (r
2 hat  0.4) were included in the analysis.
Pathway databases. The Gene Set Enrichment Algorithm (GSEA) modi-
ﬁed algorithm was provided as part of the GenGen suite (http://
openbioinformatics.org/gengen), complete with formatted data ﬁles using the
SNP/Gene mappings from the UCSC Genome Browser annotation in the
snp126, refGene, and refLink tables (genome build:hg18). The software uses
human biological pathways deﬁned from Gene Ontology (http://www.
geneontology.org), BioCarta (http://www.biocarta.com), and the Kyoto Ency-
clopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg)
databases (8,9). All human KEGG and BioCarta pathways were used in the
analysis, but only level 4 annotations in Biological Process and Molecular
Function from Gene Ontology. These were the latest version when down-
loaded from the Gengen website (http://openbioinformatics.org/gengen, ac-
cessed December 2007).
We also designed three artiﬁcial positive control pathways. The ﬁrst
contained 17 known type 2 diabetes loci (18 conﬁrmed variants excluding
SLC30A8 not captured on the Affymetrix chip), and the second and third
contained the same genes, diluted with 17 and 34 genes with median GWA 
2
association statistics.
Bioinformatic and statistical analysis. Analysis of pathways was per-
formed using a recently published algorithm (10). This method implements the
existing GSEA algorithm (11). Brieﬂy, 
2 disease association statistics from all
quality-controlled SNPs were mapped onto genes. The mapping process
assigns the SNP with the highest test statistic, within a 200-kb ﬂanking
window on either side of the gene, to represent the overall test statistic for an
individual gene. SNPs that are not mapped to any deﬁned gene are discarded
from further analysis, whereas SNPs within the region of multiple genes are
mapped to all. This produced a list of 303,861 SNPs in 15,114 genes. Each of
these 15,114 genes is then ranked from highest to lowest according to their
test statistic (represented by the highest associated SNP). From an initial set
of 2,077 KEGG, Gene Ontology, and BioCarta pathways, 439 pathways met the
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DIABETES, VOL. 58, JUNE 2009 1463criteria of containing between 20 and 200 GWA-captured genes. This cutoff
was selected as the optimal range for gene sets based on the power of the
algorithm. However, cutoffs of between 10 and 400 produced similar results,
with WNT-signaling ranking top.
The signiﬁcance of each pathway is then judged using a Kolmogorov-
Smirnov–like running sum statistic. This test reﬂects the overrepresentation of
pathway genes toward the top of the overall ranked gene list. An enrichment
score (ES) is produced, measuring the deviation of the association statistics in
a given gene set, compared with a set of randomly picked genes. As larger
genes will by chance harbor SNPs with higher test statistics, a normalized
enrichment score (NES) is also produced, adjusting for gene size through
permutation-based label swapping. By subtracting the mean permuted ES
score from the observed ES score and dividing by the SD of the permuted ES
scores, different-sized genes and gene sets are directly comparable. A total of
10,000 permutations were performed, where the case/control ratio was
maintained during label swapping. The permutation approach gives an empir-
ical P value for an individual pathway based on label swapping, alongside a
false discovery rate calculated using NES scores from all permuted values in
all pathways examined in an experiment. Full details of formulae used in this
algorithm are provided by Wang et al. (10).
RESEARCH DESIGN AND METHODS
Biological pathway-based analysis is a complementary approach to single-
point GWA studies. The approach allows us to test the hypothesis that a set of
polymorphisms that occur in genes from a particular biological pathway or
process are associated with type 2 diabetes. Using GWA data to test for
association of a pathway rather than individual genes may provide important
novel biological insights (i.e., a pathway associated with type 2 diabetes),
which have been missed by the focus on only the most associated individual
variants. A pathway-based approach may also help prioritize individual
variants, which are at lower levels of statistical conﬁdence, for follow-up in
large replication efforts.
Pathway-based approaches have been used extensively for analyzing gene
expression data. For example, Mootha et al. (12) used the GSEA approach to
identify a set of genes involved in oxidative phosphorylation, whose expres-
sion was coordinately decreased in muscle from diabetic patients compared
with control subjects. Wang et al. (10) recently published a modiﬁed version
of the GSEA, which is designed to analyze genome-wide SNP association
statistic data rather than expression data. No GWA pathway–based analyses
have yet been performed for type 2 diabetes. In this study, we attempted to
identify pathways associated with type 2 diabetes by applying the modiﬁed
GSEA method to a type 2 diabetes GWA dataset.
We used individual level GWA data from the WTCCC type 2 diabetes study
(1,7). We used a total of 393,143 autosomal SNPs genotyped across 1,924 case
subjects and 2,938 population-based control subjects. We analyzed 439
pathways deﬁned by the Gene Ontology (8), BioCarta, and KEGG (9)
databases. Details of the algorithm used are provided in RESEARCH DESIGN AND
METHODS, but brieﬂy, the most strongly associated SNP from a gene 200 kb of
ﬂanking sequence either side is used to represent each gene in the genome.
Overlap is possible, where the same SNP can be mapped to multiple genes. An
individual gene set is then assigned a statistic based on the trend for its genes
to appear toward the top of the ranked association list of all genes in the
genome.
RESULTS
A total of 26 pathways reached a nominal P  0.05, slightly
higher than the number expected by chance (0.05  439 
22) (Table 1, Fig. 1). No pathways were associated with
type 2 diabetes at P  0.05 after Bonferroni adjustment
(top P  0.31). A quantile quantile (QQ) plot of the 439
pathways is shown in Fig. 1. The WNT-signaling pathway
was the most strongly associated and was of interest
because it contains TCF7L2, a common variation that
shows the strongest association with type 2 diabetes in all
type 2 diabetes GWA studies (7). Excluding the TCF7L2
gene from analysis ranked the WNT-signaling pathway
second out of the 439 pathways (nominal P  0.002). WNT
signaling has been proposed as an important candidate
pathway for type 2 diabetes, not only because of the
TCF7L2 association but because of its potential impor-
tance in 	-cell development and function (13–15). We
therefore investigated the WNT-signaling pathway associ-
ation using summary-level data from an additional 2,625
case subjects and 2,641 control subjects from the DGI (2)
TABLE 1
All pathways with nominal P  0.05 in WTCCC data
Database Pathway Size P (Padj) False discovery rate
KEGG WNT signaling pathway 126 0.0007 (0.31) 0.20
KEGG Olfactory transduction 26 0.0009 (0.4) 0.37
GO Organic acid biosynthetic process 30 0.004 (1) 0.60
GO Regulation of Wnt receptor signaling pathway 24 0.005 (1) 0.51
GO Odontogenesis 22 0.005 (1) 0.54
GO Aminoglycan metabolic process 32 0.007 (1) 0.53
GO Membrane invagination 62 0.009 (1) 0.51
GO Calcium-dependent cell-cell adhesion 20 0.01 (1) 0.60
KEGG Galactose metabolism 26 0.01 (1) 0.53
BioCarta ALK in cardiac myocytes 32 0.01 (1) 0.46
GO Biomineral formation 30 0.02 (1) 0.64
GO Endocytosis 131 0.02 (1) 0.64
GO Gonad development 22 0.02 (1) 0.63
GO Sensory organ development 59 0.03 (1) 0.74
BioCarta WNT signaling pathway 20 0.03 (1) 0.72
KEGG Pyruvate metabolism 38 0.03 (1) 0.76
GO Monosaccharide metabolic process 115 0.03 (1) 0.78
GO Cysteine-type peptidase activity 114 0.03 (1) 0.77
GO Carbohydrate biosynthetic process 73 0.04 (1) 0.82
GO GABA receptor activity 20 0.04 (1) 0.81
KEGG Type II diabetes 36 0.04 (1) 0.82
GO Positive regulation of transport 26 0.04 (1) 0.78
KEGG TGF-	 signaling pathway 73 0.04 (1) 0.79
GO Epidermal cell differentiation 45 0.05 (1) 0.75
GO Epidermis morphogenesis 45 0.05 (1) 0.75
BioCarta Regulation of PGC-1a HDAC5 21 0.05 (1) 0.82
Results based on 10,000 permutations and 439 pathways. Gene size is the number of analyzed genes within that pathway. Padj is the
Bonferroni-adjusted P value based on 439 statistical tests. GO, Gene Ontology.
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association statistics available for each of the 126 WNT-
signaling gene SNPs. A QQ plot of the meta-analyzed DGI
and FUSION results is shown in Fig. 2. There is modest
deviation away from the null distribution, but this is within
the 95% concentration intervals. Details of the WNT-
signaling SNPs reaching P  0.01 are given in Table 2 and
for all 126 SNPs in Supplementary Table 1 (found in an
online-only appendix at http://diabetes.diabetesjournals.
org/cgi/content/full/db08-1378/DC1). Expanded results are
also available for the next best 12 pathways in Supplemen-
tary Table 2.
We next assessed in which pathways the genes in the 18
conﬁrmed type 2 diabetes loci occurred (Supplementary
Table 3). Based on regions deﬁned by recombination
hotspots, these 18 loci contain 23 genes, although it is
important to note that a gene outside of a recombination
hotspot may be the gene on which an associated SNP acts.
Seven pathways contained more than one gene from the 23
implicated in the 18 loci but none more than three. The
highest-ranked of these was the metallopeptidase activity
pathway, but this pathway did not reach signiﬁcance (P 
0.19). We also designed three artiﬁcial positive control
pathways to assess what proportion of real loci need to be
present in a pathway for it to be detected. The ﬁrst
contained the most strongly associated SNP from each of
17 known type 2 diabetes loci (6) (excluding SLC30A8 not
captured on the Affymetrix chip); the second and third
contained the same SNPs, diluted with 17 and 34 SNPs
with median GWA 
2 association statistics. Analysis of
these 17, 34, and 51 gene pathways, together with the 439
database-deﬁned pathways, ranked each positive control
pathway at the top, with nominal P values 0.0001. The 17
and 34 gene pathways reached signiﬁcance after multiple
testing (false discovery rate statistics of 0.006 and 0.02,
respectively), but the pathway consisting of 51 genes did
not (false discovery rate 0.09).
DISCUSSION
The main implication of our results is that type 2 diabetes
genes fall in multiple pathways. This is consistent with the
observation that, of the 23 genes implicated from the
current 18 conﬁrmed loci, a maximum of three fall in the
same pathway. There are two main limitations to our
study. First, we are limited by the accuracy and complete-
ness of publicly available pathway databases. While de-
ﬁned pathways were used from three separate data
sources, there is clearly an incomplete knowledge of
biological and disease pathways. Second, results from our
artiﬁcially created positive control pathways indicate that
pathways need to have a large proportion of genes asso-
ciated before they reach experiment-wise signiﬁcance (for
example, a pathway containing variants representing 17
conﬁrmed loci and 34 nonassociated loci does not reach
P  0.05 after correcting for the number of pathways
tested).
A further limitation is that the best approach to generate
an association statistic for a set of genes is unclear. Large
linkage disequilibrium (LD) blocks around strongly asso-
ciated genes can hugely inﬂate the signiﬁcance of an
individual pathway and can introduce the problem of
nonindependence across genes and pathways. Although
this problem was overcome in the GSEA algorithm by
selecting a single SNP to represent a gene, this in itself is
limiting. A true disease-associated gene may have multiple
functional variants. By representing each gene locus with
a single SNP, we are therefore missing out on the potential
effect of multiple association signals for a given gene. A
better gene statistic would evaluate all the variation across
a locus, rather than just the SNP with the best association
statistic, while accounting for any LD.
Despite our conclusion that diabetes genes are likely to
reside in multiple pathways, it is still interesting to note
that the second highest–ranked pathway was the WNT-
signaling pathway, after the exclusion of TCF7L2. Multiple
studies have suggested that tight regulation of WNT sig-
naling is required for normal pancreatic development
during embryonic growth (13–15). Several WNT-signaling
genes, with SNPs associated at nominal P  0.01, are
worth noting. These include the CCND2 gene, a cyclin
upregulated in islet compared with whole pancreas
(rs11833537 P  0.003), and the SMAD3 (rs7178347 P 
0.0006) and PRICKLE1 (rs1796390 P  0.001) genes,
which are both expressed in the fetal pancreas (data from
http://www.cbil.upenn.edu/epcondb42).
It was previously shown by Mootha et al. (12), using
expression data, that the oxidative phosphorylation path-
way was associated with type 2 diabetes. In our analysis,
using GWA data, the oxidative phosphorylation pathway
ranked 431 of the 439 pathways (P  0.98). The most likely
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FIG. 1. Dashed lines denote 95% concentration intervals.
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FIG. 2. P values based on meta-analyzed DGI and FUSION data. Dashed
lines denote 95% concentration intervals. Plot excludes association
signal for TCF7L2.
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phosphorylation gene expression are caused by the dis-
ease, rather than the gene expression changes causing
type 2 diabetes.
In conclusion, using type 2 diabetes GWA data and a
pathway-based approach, we found that the WNT-signal-
ing pathway ranked highest; however, SNPs from this
pathway did not show convincing association in additional
studies. The failure to ﬁnd a highly associated individual
pathway could be explained by the genetic architecture of
type 2 diabetes, the power of the analysis, or the strength
and completeness of the algorithms and pathway datasets
used. Pathway-based approaches may be more successful
for some complex traits than others, depending on the
nature of the underlying disease physiology.
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